U.S. Markets open in 8 hrs 27 mins

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
253.33+5.23 (+2.11%)
At close: 4:00PM EDT
People also watch
CELGREGNGILDAMGNALXN
  • So AMGN misses earnings, fails a phase 3 safety study and barely goes down on either event. Biogen beats earnings, acquires a phase 3 start up and has dropped $45 in a month. Makes sense.
  • can't hold the gain
  • Regarding the BIIB / Roche news... I can't imagine that had any play today. The press release is kind of misleading on who is to blame, but it kind of points the finger at Roche. Roche blames BIIB. If people though BIIB caused it, this thing would have tanked -50 in its current condition. If people thought Roche did it and the drug would be pulled or something, BIIB would have been up a lot more then +5.
  • So why the rise? oversold? wish news was coming
  • Would paying out a dividend help? I'd rather they acquire like they are doing, but the stock is complete garbage right now. It needs something to lift it.
  • Nice day today, on higher volume. Nice bounce off of $246. We didn't hold onto the day high, but let's see some follow through for the rest of the week. We all know this can be -$7 tommorow :(.
  • Drops everyday. Powerful Sell program.
  • There's many reason why BIIB is going down lately. Firstly as Morgan Stanley points it out there won't be buyouts, secondly and the most investors concerning about is a new MS drug that will eating away Biogen MS franchise and thirdly the Biotech sector cannot break out of the doldrums. But for Biogen the next earning report will give a clearer picture how much new drug takes its market share and how much royalty they get and their Spinraza drug sale progress. Biogen gave a great guidance for 2017 earnings which is more than $20 per share and they bested in the first quarter. A lot of Analysts still very bullish about Biogen but few are very skeptical. Next Earnings will clear this up. I think there are a lot of things going for Biogen in the long term (1 to 2 yrs) investors will be very well rewarded.
  • RALLLLLLLLLYYYYYYYYYYYY ..CHEAPEST BIOTECH HERE
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation May
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjcwNTc4fENoaWxkSUQ9Mzc3ODc0fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.

  • Hard to believe this stock was $290 on April 25th. A whopping $45 drop on no news! Where's this ramp-up of Spinraza promised by the CFO during the cc?
  • REGNBIIB SHAREHOLDERS AND BIOTECH INVESTORS:

    BMY and MRK promising blockbuster PD1 Inhibitor Keytruda and Opdivo beginning combination trials with NWBO DC-Vax-L.
    NWBO shares already beginning to move up now as investors realize major positive announcements from 10 year brain cancer phase III trial are likely next week at ASCO.

    Company already announced in February that it had met the Primary Progression Free Survival Endpoint and that not yet for Overall Survival but expected in this current timeframe.

    Shares have been under extreme selling pressure from negative press by the usual short seller advocates.

    Expected news could cause EXTREME PRICE INCREASE.
    https://finance.yahoo.com/news/nw-bio-announces-lifting-clinical-143000739.html

    NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached
    BETHESDA, Md., Feb. 6, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Compa
    finance.yahoo.com
  • good news for biogen today like like like

    === The European Commission (EC) has granted a standard marketing authorization for FAMPYRA (prolonged-release fampridine tablets) for walking improvement in people with multiple sclerosis (MS), Biogen (BIIB) announced today. The approval is based on the results of the Phase 3 ENHANCE study, which confirm the clinically meaningful benefits and safety of FAMPYRA over the long term in people with both relapsing and progressive forms of MS. The ENHANCE study was conducted following the EC’s conditional marketing authorization for FAMPYRA in 2011. FAMPYRA can be used alone or with existing MS therapies, including immunomodulatory drugs.
  • I'm calling this recent selloff the Clancy dip. Remember when he sold right into earnings release at $290 p/s! Numerous downgrades appeared following that event! Sure hope this gain will hold today! Management actions definitely can affect the price movement and sentiment.
  • why it continue down, any good suggestion for what should I do, thanks
  • In all seriousness, where do you guys think the bottom is? Last couple of times it tanked, it went all the way to $225. Goes through all support levels like nobodies business. I think this has been down every day since earnings except maybe 3! Aside from the one day that it went up $4 on the purchase, the other 2 days were < $1 following long losing streaks.
  • So we roughly bounced off of 275 4 times in the past 2 yrs, we sliced through that no problem. Did a couple small bounces off 245... bounced off of 225 *hard* and ran up to 330 and in 1 month... then went back to tanking. This stock has had long periods of tanking... but there have always been bounces along the way. Never seen such a flat line down.
  • I'm beginning to understand why our grandparents stashed money under their mattresses!
  • good news finally but maybe a buck or two. this dog is hurting.
  • now you know why were up. riches drug caused a death. biib sales to rocket.
  • pfe, you're close by. offer 325 and take these idiots out.